Repligen Co. (NASDAQ:RGEN) Shares Acquired by Handelsbanken Fonder AB

Handelsbanken Fonder AB lifted its position in shares of Repligen Co. (NASDAQ:RGEN) by 8.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,633 shares of the biotechnology company’s stock after purchasing an additional 1,200 shares during the period. Handelsbanken Fonder AB’s holdings in Repligen were worth $2,106,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Ballentine Partners LLC grew its position in shares of Repligen by 4.0% in the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock valued at $270,000 after buying an additional 72 shares during the last quarter. CIBC Asset Management Inc boosted its stake in Repligen by 5.0% in the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company’s stock valued at $246,000 after acquiring an additional 81 shares in the last quarter. MML Investors Services LLC grew its holdings in shares of Repligen by 2.7% during the third quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock worth $503,000 after purchasing an additional 89 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Repligen by 15.2% during the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 90 shares in the last quarter. Finally, Louisiana State Employees Retirement System lifted its holdings in shares of Repligen by 0.7% in the 4th quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company’s stock valued at $2,087,000 after purchasing an additional 100 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Trading Down 2.0 %

NASDAQ RGEN opened at $161.47 on Wednesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen Co. has a one year low of $113.50 and a one year high of $203.13. The company’s 50 day moving average price is $155.30 and its 200 day moving average price is $148.57. The firm has a market capitalization of $9.05 billion, a price-to-earnings ratio of -316.61, a PEG ratio of 4.54 and a beta of 0.99.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. On average, sell-side analysts predict that Repligen Co. will post 1.72 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. StockNews.com cut Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. Canaccord Genuity Group began coverage on shares of Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $180.00 price target on shares of Repligen in a research note on Friday, February 21st. JPMorgan Chase & Co. lifted their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Finally, Canaccord Genuity Group increased their target price on shares of Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and an average price target of $181.00.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.